利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.025 秒)

    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    2.
    发明申请
    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS 审中-公开
    表达结构性HCV抗原的重组MVA

    公开(公告)号：US20110293656A1

    公开(公告)日：2011-12-01

    申请号：US13110471

    申请日：2011-05-18

    申请人： Gerd Sutter ,  Volker Erfle ,  Caroline Staib ,  Yuan Wang ,  Guangdi Li ,  Li-Xin Zhu

    发明人： Gerd Sutter ,  Volker Erfle ,  Caroline Staib ,  Yuan Wang ,  Guangdi Li ,  Li-Xin Zhu

    IPC分类号： A61K39/285 ,  C07H21/04 ,  C12N5/10 ,  A61P31/18 ,  A61P31/12 ,  C12N7/01 ,  A61K35/76 ,  C07H21/02

    CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5256 ,  A61K2039/57 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2770/24234 ,  C12N2770/24243

    摘要： The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

    摘要翻译： 本发明涉及能够表达结构HCV抗原，所述结构抗原的功能部分或所述结构抗原表位的重组MVA。 本发明进一步涉及一种药物组合物，特别是疫苗形式，并含有本发明的重组体MVA，其含有本发明的重组MVA的真核细胞以及重组MVA的各种用途，例如用于产生重组结构 蛋白质，用于制备适于治疗和预防由此引起的HCV感染和疾病的药物制剂。 本发明还涉及用于产生由所述重组MVA编码的重组MVA和重组结构HCV多肽以及所述重组MVA的DNA或RNA的方法。

    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    3.
    发明申请
    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS 审中-公开
    表达结构性HCV抗原的重组MVA

    公开(公告)号：US20090238843A1

    公开(公告)日：2009-09-24

    申请号：US12476696

    申请日：2009-06-02

    申请人： Gerd Sutter ,  Volker Erfle ,  Caroline Staib ,  Yuan Wang ,  Guangdi Li ,  Li-Xin Zhu

    发明人： Gerd Sutter ,  Volker Erfle ,  Caroline Staib ,  Yuan Wang ,  Guangdi Li ,  Li-Xin Zhu

    IPC分类号： A61K39/12 ,  C12N5/10 ,  C07H21/04

    CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5256 ,  A61K2039/57 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2770/24234 ,  C12N2770/24243

    摘要： The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

    摘要翻译： 本发明涉及能够表达结构HCV抗原，所述结构抗原的功能部分或所述结构抗原表位的重组MVA。 本发明进一步涉及一种药物组合物，特别是疫苗形式，并含有本发明的重组体MVA，其含有本发明的重组MVA的真核细胞以及重组MVA的各种用途，例如用于产生重组结构 蛋白质，用于制备适于治疗和预防由此引起的HCV感染和疾病的药物制剂。 本发明还涉及用于产生由所述重组MVA编码的重组MVA和重组结构HCV多肽以及所述重组MVA的DNA或RNA的方法。

    USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS
    7.
    发明申请
    USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS 审中-公开
    重组修饰的疫苗病毒安非他明（MVA）用于治疗包括人类在内的生活动物中的1型超感染性

    公开(公告)号：US20090191157A1

    公开(公告)日：2009-07-30

    申请号：US12282975

    申请日：2007-03-14

    申请人： Melanie Albrecht ,  Gerd Sutter ,  Yasemin Suezer ,  Gerald Reese ,  Stefan Vieths ,  Caroline Staib

    发明人： Melanie Albrecht ,  Gerd Sutter ,  Yasemin Suezer ,  Gerald Reese ,  Stefan Vieths ,  Caroline Staib

    IPC分类号： A61K35/76 ,  C12N7/01 ,  C07H21/00

    CPC分类号： A61K39/35 ,  A61K2039/5256 ,  C07K14/77 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2710/24171

    摘要： The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods.

    摘要翻译： 本发明涉及包含异源核酸的重组修饰的痘苗病毒安卡拉（MVA）在制备用于预防和/或治疗包括人的活动物中的I型超敏反应的药物中的用途。 本发明还涉及包含异源核酸的重组修饰的痘苗病毒安卡拉（MVA），其中所述异源核酸被并入MVA的基因组的非必需区域中，所述异源核酸在 例如 痘苗病毒特异性启动子，并且异源核酸选自编码选自杂草花粉，草花粉，树花粉，螨，动物，真菌，昆虫，橡胶，蠕虫，人类的变应原的核酸组 自身过敏原和食物。